Aurobindo Pharma Limited (NSE: AUROPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 708.58B |
| Revenue (ttm) | 302.95B |
| Net Income (ttm) | 35.82B |
| Shares Out | 580.80M |
| EPS (ttm) | 61.31 |
| PE Ratio | 19.90 |
| Forward PE | 16.53 |
| Dividend | 3.00 (0.24%) |
| Ex-Dividend Date | n/a |
| Volume | 879,807 |
| Open | 1,239.15 |
| Previous Close | 1,235.40 |
| Day's Range | 1,232.05 - 1,267.35 |
| 52-Week Range | 958.50 - 1,592.00 |
| Beta | 0.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibi... [Read more]
Financial Performance
In 2023, Aurobindo Pharma's revenue was 290.02 billion, an increase of 16.68% compared to the previous year's 248.55 billion. Earnings were 31.73 billion, an increase of 64.62%.
Financial StatementsNews
Q2 2025 Aurobindo Pharma Ltd Earnings Call Transcript
Q2 2025 Aurobindo Pharma Ltd Earnings Call Transcript
Stocks to watch today: Divi’s Laboratories, JSW Steel, LIC, Biocon in focus; Asian Paints, Tata Motors, Aurobindo Pharma, Ola Electric under pressure
In today’s market action, key stocks to watch include Divi’s Laboratories, which reported better-than-expected results, and JSW Steel, which has been chosen as the preferred bidder for new coal blocks...
Aurobindo Pharma Q2 net profit rises 9%
Aurobindo Pharma witnessed a nearly 9% surge in consolidated net profit for Q2FY25, reaching Rs 817 crore. This growth was fueled by an 8% rise in consolidated revenue, driven by a strong performance ...
Aurobindo Pharma Q2 FY25 Results: Revenue at ₹7,796.07 crore, up 8.9% YoY; Profit at ₹816.95 crore, up 8.6% YoY
Aurobindo Pharma reported its Q2 FY25 results, showcasing a steady year-on-year (YoY) growth. The company’s total revenue from operations reached ₹7,796.07 crore, marking an 8.9% increase compared to ...
Lupin and Aurobindo Pharma shares in focus on positive US generics outlook; Macquarie sees potential rally
Lupin Ltd and Aurobindo Pharma Ltd stocks moved upwards in early trade, with Lupin’s shares trading at ₹2,194.50, marking a 0.58% increase, while Aurobindo Pharma stood at ₹1,399.50, up by 0.18% as of...
Pharma Sector Stocks: Granules down 1.68%, Akums slips 1.29%, Zydus Life up 0.13%, Aurobindo Pharma gains 0.99% in early trade
Time Stamp: November 4, 2024, 9:41 AM Market Update: Pharma stocks opened with a mixed trend today, showing slight gains and losses among the major players. SPARC: Down by 1.81%, trading at ₹212.04 PP...
Quant Active Fund sees 36.74% returns in last year, top holdings in Reliance Industries & Aurobindo Pharma
Quant Active Fund Direct-Growth is Quant Mutual Fund’s equity mutual fund scheme. The fund has an AUM of ₹11,229.42 crores and the current NAV is ₹717.820 as of November 1, 2024. The return performanc...
Quant Mid Cap Fund sees 44.61% returns in last year, top holdings in Reliance Industries & Aurobindo Pharma
Quant Mid Cap Fund Direct-Growth is Quant Mutual Fund’s equity mutual fund scheme. It has an AUM of ₹9,500.70 crores and the latest NAV is ₹253.533 as of November 1, 2024 The return performance of the...
Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%
As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...
Aurobindo Pharma shares jump 2% after BOCAPS upgrades to ‘Buy’ rating
Aurobindo Pharma shares jumped more than 2% after brokerage firm BOCAPS upgraded the company’s rating to ‘Buy’, raising the target price from ₹1,200 to ₹1,728 per share. Eugia’s sales goal of about US...
BOCAPS upgrades Aurobindo Pharma to ‘Buy’ with a revised target price – check details
BOCAPS has upgraded Aurobindo Pharma’s rating to ‘Buy’, raising the target price from ₹1,200 to ₹1,728 per share. The company is undergoing a transformation, shifting its focus from APIs to biologics ...
Brokerage Updates: Key calls on Zomato, Tata Motors, Nykaa, Zomato, Godrej Properties, Aurobindo Pharma, M&M, Info Edge, and more
Brokerage Reports Highlight Target Prices for Tata Motors, Nykaa, Info Edge, Godrej Properties, Skipper, Trent, Aurobindo Pharma, and more stocks.
UBS maintains sell on Aurobindo Pharma, expects 8% downside from current share price
UBS has maintained a Sell rating on Aurobindo Pharma, with a target price of Rs 1,333, suggesting an 8% downside from the current price of Rs 1,453.00. The rating follows a week-long inspection of Aur...
Stocks to Watch on Oct 3: Reliance Power, Ashoka Buildcon, CESC, SMS Pharma, PVR INOX, Zydus Lifesciences, Reliance Infra, and HealthCare Global in focus
Key stocks to watch include Ashoka Buildcon, CESC, SMS Pharmaceuticals, PVR INOX, HealthCare Global Enterprises, Zydus Lifesciences, Reliance Power, Reliance Infra, Vikas Lifecare, Eraaya Lifespaces, ...
Aurobindo Pharma gets USFDA nod for Cephalexin Tablets USP, 250 mg and 500 mg
Aurobindo Pharma Limited has recently informed exchanges that the US Food and Drug Administration (USFDA) has granted final approval to manufacture and market Cephalexin Tablets USP, 250 mg and 500 mg...
Aurobindo Pharma shares fall 3% after US FDA issues 10 observations after inspection
Aurobindo Pharma shares dropped more than 3% after the United States Food and Drug Administration (US FDA) completed its inspection at Unit II of Apitoria Pharma Private Limited, a wholly-owned subsid...
Aurobindo Pharma faces setback as US FDA issues 10 observations after inspection
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) has completed its inspection at Unit II of Apitoria Pharma Private Limited, a wholly-owned subsidiary of Aurobin...
UBS initiates Sell call on Zydus, Dr Reddy’s, Aurobindo Pharma, Lupin
UBS has initiated sell ratings on key Indian pharmaceutical stocks including Zydus, Dr. Reddy's, Aurobindo, and Lupin, citing overestimated core margins and slow growth in their primary markets of Ind...
Eugia Steriles receives US FDA clearance for injectable facility
Aurobindo Pharma’s 100% stepdown subsidiary, Eugia Steriles Private Limited, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its...
Aurobindo arm gets USFDA nod
Hyderabad: Aurobindo Pharma on Wednesday said that its stepdown subsidiary, Eugia Steriles, got approval from US drug regulator, USFDA.
LIC reduces stake in Aurobindo Pharma to 2.26% from 5.01%
Life Insurance Corporation of India (LIC) has announced a reduction in its shareholding in Aurobindo Pharma Ltd. LIC’s stake in the company has decreased from 5.01% to 2.265% of the paid-up capital, w...
FDC shares surge 11%, leading gains in BSE Healthcare index
Shares of FDC Limited surged by 11.22% today, reaching ₹642.95, making it one of the top performers in the BSE Healthcare Index. The index itself was up 1.0%, with other top gainers including Hikal Ch...
Aurobindo Pharma share jumps 4% after Eugia Steriles gets USFDA nod for anesthetic drug
Aurobindo Pharma shares jumped more than 4% in morning trade after its stepdown subsidiary, Eugia Steriles received its first product approval from the United States Food and Drug Administration (USFD...
Planful of US to invest $120m in expanding its Hyderabad R&D hub
Aurobindo Pharma's stepdown subsidiary, Eugia Steriles Private Ltd, has received its first product approval from the US FDA for Lidocaine Hydrochloride injection. The approval came after an inspection...
Aurobindo arm Eugia Steriles' new injectable unit gets 1st product nod from USFDA
Aurobindo Pharma's stepdown subsidiary, Eugia Steriles Private Ltd, has received its first product approval from the US FDA for Lidocaine Hydrochloride injection. The approval was granted following an...